Jessica A. Hellyer

Oncology
1204 N Vercler Rd
Spokane Valley, WA 99216

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.

Showing 1-12 of 25

Last Updated: 09/26/2026